XCSport体育
About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
XCSport体育:Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
XCSport体育:Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
XCSport体育:Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Popular Science
XCSport体育:Highlights
Download
Media Reports
Media Enquiry
2024-10-27
Henlius Announces NMPA Approvals of Two ADC Candidates for IND
2024-10-27
Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India
2024-10-25
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
2024-10-24
Results From the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO
2024-10-24
Results From the Preclinical Study of HLX42, a Potential BIC EGFR-Targeting ADC Released at 2023 ESMO
2024-10-20
Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU
2024-10-12
Henlius Will be at CPHI Barcelona 2023
2024-10-11
Henlius Xuhui Facility Passes GMP Inspection for HANSIZHUANG by PIC/S Member BPOM
2024-09-22
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
1
2
3
4
5
...
8